Workflow
ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson’s Disease
ZVSAZyVersa Therapeutics(ZVSA) GlobeNewswire·2025-04-29 11:57

Core Insights - ZyVersa Therapeutics, Inc. announces promising data for its Inflammasome ASC Inhibitor IC 100, which may slow the progression of Parkinson's disease [1][3] - The study published in npj Parkinson's Disease shows that IC 100 blocks microglial inflammasome activation and reduces neurotoxic alpha-synuclein accumulation, both critical in Parkinson's disease progression [2][7] Company Overview - ZyVersa is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for inflammatory and renal diseases, with a significant market opportunity exceeding 100billion[10]−ThecompanyisadvancingitsleadcandidateIC100,ahumanizedIgG4monoclonalantibodytargetinginflammasomeadaptorproteinASC,whichisdesignedtomitigateinflammatoryresponses[6][10]StudyFindings−TheresearchindicatesthatIC100uniquelyinhibitsASCspeckactivityandmisfoldedproteinaggregates,makingitastrongcandidatefortreatingneurodegenerativediseases,includingLewybodydementiaandAlzheimer′sDisease[5]−ThestudyhighlightsthepresenceofASCandNLRP1inalpha−synucleinaggregatesinneuronalLewybodies,suggestingalinkbetweeninflammasomeactivationandneurodegenerationinParkinson′sdisease[8]MarketContext−TheglobalParkinson′sdiseasedrugmarketwasvaluedat100 billion [10] - The company is advancing its lead candidate IC 100, a humanized IgG4 monoclonal antibody targeting inflammasome adaptor protein ASC, which is designed to mitigate inflammatory responses [6][10] Study Findings - The research indicates that IC 100 uniquely inhibits ASC speck activity and misfolded protein aggregates, making it a strong candidate for treating neurodegenerative diseases, including Lewy body dementia and Alzheimer's Disease [5] - The study highlights the presence of ASC and NLRP1 in alpha-synuclein aggregates in neuronal Lewy bodies, suggesting a link between inflammasome activation and neurodegeneration in Parkinson's disease [8] Market Context - The global Parkinson's disease drug market was valued at 6.6 billion in 2024 and is projected to reach $13.3 billion by 2034, indicating significant growth potential for innovative treatments [7]